Noga Yerushalmi
Head of Israel Bio-incubator @ M Ventures
Noga Yerushalmi is a Series A investor at M Ventures focused on Health Care and Medical. Noga joined the team in January 2017 and is the Head of the Bioincubator in Insrael. Noga is a graduate of Tel-Aviv University, and did her postdoctoral fellowship at NIH, USA. She has over 15 years of experience in the Israeli Biotech industry, leading R&D projects in different research fields and business development opportunities.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Noga Yerushalmi invests in
Stages Noga Yerushalmi invests in
Countries Noga Yerushalmi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (100%)
- Medical 1 (50%)
- Life Science 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Stage
- Series A 1 (50%)
- Venture - Series Unknown 1 (50%)
Country
- Israel 1 (50%)
- Norway 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M / Series A / Jul 09, 2025 | ||
| Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects. | $14M / Venture - Series Unknown / Apr 03, 2024 |
Co-Investors
About M Ventures
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
M Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christian Patze
Associate, Performance Materials
|
|||
|
Noga Yerushalmi
Head of Israel Bio-incubator
|
|||
Sarah Luppino
Associate
|
|||
Alexander Hoffmann
Principal
|
|||
Alicia Iruzun Lafitte
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Noga Yerushalmi invest in?
Noga Yerushalmi invests primarily in Health Care, Medical and Life Science startups, most often at Series A and Venture - Series Unknown stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Noga Yerushalmi?
Public channels for Noga Yerushalmi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Noga Yerushalmi last invest?
The most recent investment recorded for Noga Yerushalmi closed in Jul 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
